Biocon buys Viatris biosimilars unit for $3.34 bln; Infosys launches 'Metaverse

Biocon Biologics has struck a $3.335 billion cash-and-stock deal with US pharmaceuticals company Viatris to acquire its global biosimilars business including rights in the partnered in-licensed portfo

Forbes India Podcasts

From the Bookshelves

Forbes India Tech conversations

Money Talks

One thing today in Tech

Advertisement
Advertisement